echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Aiming at "gradual freezing"!

    Aiming at "gradual freezing"!

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    Recently, Magpie Medicine's Class 1 new drug nitroxazine for the treatment of amyotrophic lateral sclerosis (ALS) has obtained the implied approval of the US FDA clinical trial, and a phase 1 clinical bridging trial will be launched in the United States


    Founded in 2011, Magpie Medicine is a clinical-stage company focusing on the research and development of innovative treatments for cardiovascular and mitochondrial diseases


    Nitrazine is a class 1 chemical innovation drug exclusively transferred from Jinan University by Magpie Medicine, and it has a unique mechanism of action


    In China, nitroxazine tablets are currently undergoing a phase 2 clinical study for the treatment of ALS, aiming to evaluate the efficacy, safety and PK characteristics of nitroxazine tablets in ALS patients


    Amyotrophic lateral sclerosis, commonly known as "gradual freezing syndrome", is a fatal neurodegenerative disease characterized by the progressive degeneration of brain and spinal cord motor neurons


    Note: The original text has been deleted

    Reference materials:

    [1] Magpie Medicine's class 1 chemical innovative drug for treatment of amyotrophic lateral sclerosis, nitroxazine tablets, was approved by the US FDA for clinical trials.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.